Cortot, A. B., Audigier-Valette, C., Molinier, O., Le Moulec, S., Barlesi, F., Zalcman, G., Dumont, P., Pouessel, D., Poulet, C., Fontaine-Delaruelle, C., Hiret, S., Dixmier, A., Renault, P., Becht, C., Raffy, O., Dayen, C., Mazieres, J., Pichon, E., Langlais, A., Morin, F., Moro-Sibilot, D., & Besse, B. (2020). weekly paclitaxel plus bevacizumab versus docetaxel as second- or third-line treatment in advanced non-squamous non–small-cell lung cancer: Results of the IFCT-1103 ULTIMATE study. European journal of cancer, 131, 27–36. http://access.bl.uk/ark:/81055/vdc_100104110723.0x000019